Mainz Biomed Regains Compliance With Nasdaq Listing Rules

(RTTNews) - Mainz Biomed N.V. (MYNZ), a molecular genetics diagnostic company, announced on Monday, that it has regained compliance with Nasdaq's continued listing requirements.

The company received formal confirmation from Nasdaq on January 23, 2025, that it met the minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1).

Mainz Biomed had previously met the minimum bid price requirement under Rule 5550(a)(2). With this, the company is now fully compliant with all Nasdaq listing rules and will continue to be listed on the Nasdaq Capital Market.

Mainz Biomed specializes in the early detection of cancer, with its flagship product ColoAlert being a non-invasive test for colorectal cancer.

The company is also advancing other diagnostic solutions, such as PancAlert, for pancreatic cancer.

Currently, MYNZ is trading at $4.53 up by 0.89%.